Who are MVC-COV1901(6 Months)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): protein subunit: Novavax COVID-19 vaccine, MVC-COV1901(3 Months), RSV prefusion F protein-based vaccine, RSV Vaccine, R21Matrix M, R21/Matrix-M™.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/mvc-cov1901-6-months.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

MVC-COV1901(6 Months) — Competitive Intelligence Brief

MVC-COV1901(6 Months) (MVC-COV1901(6 Months)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Protein subunit vaccine. Area: Immunology / Infectious Disease.

marketed Protein subunit vaccine SARS-CoV-2 spike protein (S-2P) Immunology / Infectious Disease Biologic Live · refreshed every 30 min

Target snapshot

MVC-COV1901(6 Months) (MVC-COV1901(6 Months)) — Taoyuan General Hospital. MVC-COV1901 is a recombinant protein subunit vaccine that stimulates immune responses against SARS-CoV-2 spike protein to prevent COVID-19 infection.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
MVC-COV1901(6 Months) TARGET	MVC-COV1901(6 Months)	Taoyuan General Hospital	marketed	Protein subunit vaccine	SARS-CoV-2 spike protein (S-2P)
protein subunit: Novavax COVID-19 vaccine	protein subunit: Novavax COVID-19 vaccine	Novavax	marketed	Protein subunit vaccine	SARS-CoV-2 spike protein
MVC-COV1901(3 Months)	MVC-COV1901(3 Months)	Taoyuan General Hospital	marketed	Protein subunit vaccine	SARS-CoV-2 spike protein
RSV prefusion F protein-based vaccine	rsv-prefusion-f-protein-based-vaccine	Pfizer Inc.	marketed	Viral protein subunit vaccine	Respiratory syncytial virus fusion (F) protein
RSV Vaccine	RSV Vaccine	Pfizer	marketed	Recombinant protein subunit vaccine	Respiratory syncytial virus (RSV) fusion (F) glycoprotein
R21Matrix M	R21Matrix M	London School of Hygiene and Tropical Medicine	phase 3	Recombinant protein subunit vaccine	Plasmodium falciparum circumsporozoite protein (CSP)
R21/Matrix-M™	R21/Matrix-M™	University of Oxford	phase 3	Recombinant protein subunit vaccine	Plasmodium falciparum circumsporozoite protein (CSP)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Protein subunit vaccine class)

Novavax · 2 drugs in this class
Taoyuan General Hospital · 2 drugs in this class
Medigen Vaccine Biologics Corp. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). MVC-COV1901(6 Months) — Competitive Intelligence Brief. https://druglandscape.com/ci/mvc-cov1901-6-months. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab